Alnylam Pharmaceuticalsvs.Biogen
ALNY vs BIIB · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals and Biogen are similar in size by market cap; year to date, Biogen leads (+23.9% vs −40.6%).
Side by side
| ALNY | BIIB | |
|---|---|---|
| Market cap | $30.4B | $31B |
| Price | $240.08 | $220.77 |
| Today | +1.7% | +1.2% |
| Return YTD | −40.6% | +23.9% |
| Return 1Y | −48.1% | +56.6% |
| P/E | 37.6 | 37.2 |
| P/S | 6.3 | 3.1 |
| P/B | 22.4 | 1.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →More ALNY & BIIB comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and BIIB sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →